PDCD1 and Increased total eosinophil count: In a retrospective cohort based on a pharmacovigilance registry that included 909 patients with various tumors receiving anti-PD-1 or anti-PD-L1 therapy, 2.8% of patients were found to have immune-related eosinophilia, the majority of whom were being treated for advanced melanoma (58).